CS
TXMD icon

Credit Suisse’s TherapeuticsMD TXMD Stock Holding History

Credit Suisse’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4
Closed – – 4299
2022
Q2 		$0 Sell
4
-852
-100% -$8.14K ﹤0.01% 4324
2022
Q1 		$16K Buy
856
+163
+24% +$2.56K ﹤0.01% 3543
2021
Q4 		$12K Sell
693
-7,300
-91% -$219K ﹤0.01% 4459
2021
Q3 		$296K Buy
7,993
+311
+4% +$13.8K ﹤0.01% 4092
2021
Q2 		$457K Buy
7,682
+2,316
+43% +$140K ﹤0.01% 3898
2021
Q1 		$359K Sell
5,366
-1,600
-23% -$125K ﹤0.01% 3935
2020
Q4 		$421K Buy
6,966
+2,432
+54% +$166K ﹤0.01% 3875
2020
Q3 		$358K Sell
4,534
-423
-9% -$33.7K ﹤0.01% 3554
2020
Q2 		$309K Buy
4,957
+2,241
+83% +$130K ﹤0.01% 3573
2020
Q1 		$145K Sell
2,716
-46
-2% -$4.56K ﹤0.01% 3741
2019
Q4 		$334K Buy
2,762
+12
+0.4% +$1.73K ﹤0.01% 3775
2019
Q3 		$499K Sell
2,750
-593
-18% -$83.6K ﹤0.01% 3440
2019
Q2 		$435K Buy
3,343
+630
+23% +$113K ﹤0.01% 3484
2019
Q1 		$660K Buy
2,713
+91
+3% +$24.1K ﹤0.01% 3186
2018
Q4 		$500K Buy
2,622
+661
+34% +$161K ﹤0.01% 3255
2018
Q3 		$643K Sell
1,961
-831
-30% -$255K ﹤0.01% 3157
2018
Q2 		$871K Sell
2,792
-636
-19% -$194K ﹤0.01% 3115
2018
Q1 		$835K Buy
3,428
+326
+11% +$91.5K ﹤0.01% 3072
2017
Q4 		$937K Sell
3,102
-198
-6% -$55.1K ﹤0.01% 3042
2017
Q3 		$873K Buy
3,300
+1,646
+100% +$476K ﹤0.01% 3192
2017
Q2 		$436K Sell
1,654
-50
-3% -$12.5K ﹤0.01% 3239
2017
Q1 		$614K Sell
1,704
-858
-33% -$266K ﹤0.01% 3166
2016
Q4 		$739K Buy
2,562
+502
+24% +$156K ﹤0.01% 3236
2016
Q3 		$701K Sell
2,060
-286
-12% -$104K ﹤0.01% 3231
2016
Q2 		$997K Buy
2,346
+1,083
+86% +$446K ﹤0.01% 2922
2016
Q1 		$404K Buy
1,263
+248
+24% +$84.6K ﹤0.01% 3365
2015
Q4 		$527K Sell
1,015
-103
-9% -$38K ﹤0.01% 3339
2015
Q3 		$328K Sell
1,118
-1,706
-60% -$606K ﹤0.01% 3667
2015
Q2 		$1.11M Buy
2,824
+1,653
+141% +$583K ﹤0.01% 3079
2015
Q1 		$355K Sell
1,171
-508
-30% -$124K ﹤0.01% 3764
2014
Q4 		$374K Sell
1,679
-128
-7% -$26.4K ﹤0.01% 3921
2014
Q3 		$419K Buy
1,807
+755
+72% +$190K ﹤0.01% 3755
2014
Q2 		$233K Sell
1,052
-1,364
-56% -$304K ﹤0.01% 4267
2014
Q1 		$762K Buy
2,416
+1,276
+112% +$406K ﹤0.01% 3361
2013
Q4 		$297K Buy
+1,140
New +$250K ﹤0.01% 4081
2013
Q3 		– Sell
-456
Closed -$69K – 4368
2013
Q2 		$69K Buy
+456
New +$62.5K ﹤0.01% 4072

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Credit Suisse's TXMD Position: Q3 2022 in Review

Credit Suisse sold out of TherapeuticsMD (TXMD) in Q3 2022, closing a stake of 4 shares.

Credit Suisse first reported a position in TXMD in Q2 2013 and held it in 36 quarters. The position peaked at $1.11M in Q2 2015. 43 funds tracked by Wall St. Rank hold TXMD as of Q3 2022.

  • Credit Suisse reported no remaining TherapeuticsMD position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 4 TherapeuticsMD shares in Q3 2022.
  • Credit Suisse first reported a position in TherapeuticsMD in Q2 2013 and held it in 36 quarters.
  • Credit Suisse's TherapeuticsMD position peaked at $1.11M in Q2 2015.
  • 43 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.